Literature DB >> 19325481

Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.

Cristóbal León1, Sergio Ruiz-Santana, Pedro Saavedra, Beatriz Galván, Armando Blanco, Carmen Castro, Carina Balasini, Aránzazu Utande-Vázquez, Francisco J González de Molina, Miguel A Blasco-Navalproto, Maria J López, Pierre Emmanuel Charles, Estrella Martín, María Adela Hernández-Viera.   

Abstract

OBJECTIVE: To assess the usefulness of the "Candida score" (CS) for discriminating between Candida species colonization and invasive candidiasis (IC) in non-neutropenic critically ill patients. A rate of IC <5% in patients with CS <3 was the primary end point.
DESIGN: Prospective, cohort, observational study.
SETTING: Thirty-six medical-surgical intensive care units of Spain, Argentina, and France. PATIENTS: A total of 1,107 non-neutropenic adult intensive care unit patients admitted for at least 7 days between April 2006 and June 2007.
MEASUREMENTS AND MAIN RESULTS: Clinical data, surveillance cultures for fungal growth, and serum levels of (1-3)-beta-d-glucan and anti-Candida antibodies (in a subset of patients) were recorded. The CS was calculated as follows (variables coded as absent = 0, present = 1): total parenteral nutrition x1, plus surgery x1, plus multifocal Candida colonization x1, plus severe sepsis x2. A CS >or=3 accurately selected patients at high risk for IC. The colonization index was registered if >or=0.5. The rate of IC was 2.3% (95% confidence interval [CI] 1.06-3.54) among patients with CS <3, with a linear association between increasing values of CS and IC rate (p <or= 0.001). The area under the receiver operating characteristic curve for CS was 0.774 (95% CI 0.715-0.832) compared with 0.633 (95% CI 0.557-0.709) for CI. (1-3)-Beta-d-glucan was also an independent predictor of IC (odds ratio 1.004, 95% CI 1.0-1.007). The relative risk for developing IC in colonized patients without antifungal treatment was 6.83 (95% CI 3.81-12.45).
CONCLUSIONS: In this cohort of colonized patients staying >7 days, with a CS <3 and not receiving antifungal treatment, the rate of IC was <5%. Therefore, IC is highly improbable if a Candida-colonized non-neutropenic critically ill patient has a CS <3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325481     DOI: 10.1097/CCM.0b013e31819daa14

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  116 in total

Review 1.  Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis.

Authors:  Akira Onishi; Daisuke Sugiyama; Yoshinori Kogata; Jun Saegusa; Takeshi Sugimoto; Seiji Kawano; Akio Morinobu; Kunihiro Nishimura; Shunichi Kumagai
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Authors:  P Pini; C Bettua; C F Orsi; C Venturelli; F Forghieri; S Bigliardi; L Faglioni; F Luppi; L Serio; M Codeluppi; M Luppi; C Mussini; M Girardis; Elisabetta Blasi
Journal:  Infection       Date:  2015-10-16       Impact factor: 3.553

4.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

Review 5.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

6.  Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans.

Authors:  Catiana Dudiuk; Soledad Gamarra; Cristina Jimenez-Ortigosa; Florencia Leonardelli; Daiana Macedo; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

7.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

8.  The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting.

Authors:  Ashwini Jadhav; Bhagyashree Bansode; Datta Phule; Amruta Shelar; Rajendra Patil; Wasudev Gade; Kiran Kharat; Sankunny Mohan Karuppayil
Journal:  World J Microbiol Biotechnol       Date:  2017-04-13       Impact factor: 3.312

Review 9.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

Review 10.  Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.

Authors:  Philippe Eggimann; Didier Pittet
Journal:  Intensive Care Med       Date:  2014-06-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.